Compare Air Products & Chemicals, Inc. (APD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Sana Biotechnology Inc — how do they compare? Air Products & Chemicals, Inc. trades at $296.7 (market cap $66.70B), while Sana Biotechnology Inc trades at $3.69 (market cap $1.07B). The key difference: Air Products & Chemicals, Inc. is far larger — about 62.3× Sana Biotechnology Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.42% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| APD | SANA | |
|---|---|---|
Market Cap | $66.70B | $1.07B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $5.92 |
52-Week Low | $230.42 | $2.68 |
Enterprise Value | $84.11B | $1.04B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
SANA Biotechnology trades at $3.85, down 2.04% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows significant losses with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve in 2026. Recent news highlights clinical data presentations and a $69M stock sale via ATM facility in May 2026.
Despite heavy losses, analyst sentiment is strongly bullish with 82% buy ratings, reflecting optimism for SANA's engineered cell therapies. Key risks include sustained cash burn and clinical trial outcomes. The stock's appeal hinges on pipeline success, making it suitable for risk-tolerant investors betting on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
